CD274 and neoplasm: In RKO tumor-bearing mice, PD-L1 × HYAL plus TAVO412 produced a stronger antitumor response (TGI = 66%) compared to either treatment alone: TAVO412 (TGI = 31%) or PD-L1 × HYAL (TGI = 38%) (Figure 3B).